AETERNA ZENTARIS INC (AEZS)

CA0079755017 - Common Stock

2.47  +0.03 (+1.23%)

After market: 2.5 +0.03 (+1.21%)

AETERNA ZENTARIS INC

NASDAQ:AEZS (9/28/2023, 7:00:00 PM)

After market: 2.5 +0.03 (+1.21%)

2.47

+0.03 (+1.23%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-09 2023-08-09/bmo
Earnings (Next)11-01 2023-11-01/bmo
Ins OwnersN/A
Inst Owners0.57%
Market Cap11.99M
Shares4.86M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.86
IPO12-19 1995-12-19
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AEZS Daily chart

Company Profile

Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. The company is headquartered in Summerville, New Brunswick and currently employs 21 full-time employees. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The firm is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Company Info

AETERNA ZENTARIS INC

315 Sigma Drive

Summerville NEW BRUNSWICK 29486

P: 18439003223.0

CEO: Paulini Klaus

Employees: 21

Website: https://www.zentaris.com/

AEZS News

News Image2 months ago - Aeterna Zentaris IncAeterna Zentaris Reports Second Quarter 2023 Financial Results

Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis...

News Image3 months ago - Aeterna Zentaris IncAeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards...

News Image3 months ago - Aeterna Zentaris IncAeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:...

News Image4 months ago - Aeterna Zentaris IncAeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...

News Image5 months ago - Aeterna Zentaris IncAeterna Zentaris Reports First Quarter 2023 Financial Results

– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial ...

News Image6 months ago - Aeterna Zentaris IncAeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity...

AEZS Twits

Here you can normally see the latest stock twits on AEZS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example